Atheromatous plaques in diseased arteries typically contain inflammatory cells. Rupture of atheromatous plaque is thought to be the mechanism for acute myocardial infarction and acute coronary syndrome. The most common site of plaque rupture appears to be the shoulder region where inflammatory cells are most prominent. Thus the release of acute phase reactants as a response to inflammation have been proposed as a potential marker of an "unstable" atheromatous plaque and underlying atherosclerosis.

Studies have shown a positive association between CRP and coronary artery disease. In a survey of 388 British men aged 50-69, the prevalence of coronary artery disease increased 1.5 fold for each doubling of CRP level (Mendall MA, Patel P, Ballam L, et al. C-reactive protein and its relation to cardiovascular risk factor: A population based cross sectional study. BMJ. 1996;312:1061-1065.)

Multiple prospective studies have also demonstrated that baseline CRP is a good marker of future cardiovascular events (Riker P, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med. 1998;46:391-395.)

CRP may be a good marker of cardiovascular risk in addition to lipid level.

Suitable for antigenic use in immunological protocols.

Optimal dilutions to be determined by researcher.

May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and freeze at -20°C. Aliquots are stable for 6 months after receipt at -20°C. Further dilutions can be made in assay buffer.

Human Pleural/Ascites Fluids

≥60%, RID Behring, SDS-PAGE). Sterile Filtrered (0.2um). Single band at 21kD.

~30mg/ml

Supplied as a liquid in TBS, pH 7.4. No preservative added.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.